Navigation Links
FDA Clears the Way for Generic Versions of Transdermal Patches to Treat Chronic Pain

The Food and Drug Administration (FDA) has granted approval to Mylan Technologies, Inc., for the first generic version of Alza Corporation's Duragesic Patch (Fentanyl Transdermal System) used to treat patients suffering from severe chronic pain that cannot be managed with alternative analgesics. When applied to the skin, this patch technology delivers fentanyl, an opioid pain medication that is slowly absorbed into the body through the skin providing pain relief for up to three days (72 hours).

The agency's approval is expected to provide patients with access to a lower cost alternative of this pain management system. At the same time that FDA approved Mylan's generic product, it acted on several citizens' petitions requesting that FDA deny or delay approval of the product.

The original Fentanyl Transdermal System was approved in August 1990. It is currently approved for the management of chronic pain in patients who require continuous opioid analgesia for pain that cannot be managed by acetaminophen-opioid combinations, non-steroidal analgesics, or as needed dosing with short-acting opioids.

Fentanyl is currently a Schedule II controlled substance, which is the highest level of control for drugs with a recognized medical use. As a controlled substance in Schedule II of the Controlled Substances Act (CSA), Fentanyl also comes under the jurisdiction of the Drug Enforcement Administration (DEA), which administers the CSA. Schedule II drugs are subject to manufacturing quotas set by DEA with input on medical need from FDA, distribution tracking, import and export controls, registration of prescribers and dispensers, and written prescriptions without refills.


'"/>

Source:FDA


Page: 1

Related biology news :

1. Prescription Drug Patches Gaining Ground, Tackling New Therapies
2. Discovery Could Lead To Novel Approaches In HIV Treatment
3. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
4. FDA Approves New Drug to Treat Type I and Type II Diabetes
5. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
6. Ophthalmologists Use Artificial Silicon Retina Microchip To Treat Vision Loss
7. Effective Cancer Treatments Follow The Clock
8. Potential Drug Target For Treating Cocaine Abuse Found
9. Protein Discovery Could Unlock The Secret To Better TB Treatment
10. Embryonic Stem Cells Treated With Growth Factor Reverse Hemophilia In Mice: UNC Researchers
11. Natural Killers Could Lead to New Hepatitis Treatments
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/21/2020)... Ariz. (PRWEB) , ... May 20, 2020 , ... Law ... and remove danger for all of us. The positions of these men and women ... from the defense for not following rules precisely. Officers have always had to face ...
(Date:5/15/2020)... ... 2020 , ... The National Institutes of Health (NIH) has selected McBee Moore ... and Tysons Corner, Virginia, to provide patent legal services under two separate ten (10) ... of chemistry. The firm is one of nine firms in the nation awarded a ...
(Date:5/14/2020)... ... May 13, 2020 , ... DuPont Nutrition ... enzyme for the lactose-free dairy market. This unique product allows for process optimization ... products at competitive costs across North America. , Among the numerous benefits Bonlacta™ ...
Breaking Biology News(10 mins):
(Date:5/21/2020)... BOSTON (PRWEB) , ... May 21, 2020 , ... ... disruption of clinical trials will cause long-term harm , Contrary to conventional wisdom ... Pioneer Institute study finds many companies will emerge from the pandemic commercially ...
(Date:5/15/2020)... ... 2020 , ... Children with defective heart valves often have ... adults. The reason: there are no heart valve prosthetics designed to grow with ... Defense has awarded Draper, Boston Children’s Hospital and Seattle Children’s Research Institute a ...
(Date:5/14/2020)... ... May 13, 2020 , ... In collaboration with Sartorius, Biocompare ... the Life Science Lab . The comprehensive information source was created for life ... liquid handling to contamination control. , The content hub features the latest guidance ...
(Date:5/5/2020)... ... 2020 , ... Smart Meter, a diabetes management ... LTE Cat-M Cellular Connected Diabetes Blood Glucose Monitor and Remote Patient Monitoring ... broadest cellular connectivity available, to provide patients with seamless connectivity to their physicians ...
Breaking Biology Technology: